At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer

Clinical Trial Title: 
Phase III trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer (mCRPC).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.

Clinical Trial Eligibility Criteria: 

In order to participate you must have:

  • Have histological or cytological proof of prostate cancer.
  • Have received external beam radiotherapy within the 4 weeks prior to randomization.
  • Have received four or more systemic anticancer regimens for mCRPC.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Genitourinary Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office